Company intelligence / Profile preview
Vivace Therapeutics
San Mateo, California, United Statesvivacetherapeutics.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 1
01
Overview
VT3989, a TEAD autopalmitoylation inhibitor, has been evaluated in more than 150 patients in an ongoing Phase 1 clinical study with compelling efficacy data and excellent safety profile. The company is preparing for a registrational Phase 3 clinical trial in mesothelioma[5].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Vivace Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivace Therapeutics.